Over 60% of world's HIV-1 infected individuals are in sub-Saharan African nations. In particular Zambia has one of the highest rates of infection. As in many developing countries, the academic medical community in Zambia is not enviable, and due to limited funds, meaning the emphasis in training most often focuses on clinical medicine rather than on biomedical research. Consequently, little is done to significantly improve patient care and laboratory support services. Faculty at the University of Zambia's School of Medicine (UNZA) and the University Teaching Hospital (UTH), located in the country's capital of Lusaka, recognize that to address the problem in rising cases of AIDS-associated diseases, including AIDS associated mental disorders and neurological diseases, a common and coordinated training and research program in NeuroAIDS is needed. Without such a program, it will be extremely difficult to develop the research capacity and infrastructure necessary to truly impact the country's healthcare agenda and to position faculty to compete for future research funding so that they can fully and efficiently participate in future research initiatives in HIV-associate neurological diseases. In recognition of this, we have now added this International Core as a new Core for the CHAIN Center, where we will work with our colleagues in Zambia to address these important issues.

Public Health Relevance

In this Core we will institute a training and research program to study HIV-associated neurological diseases in Zambia. This proposed program is unique, teaming Zambian and U.S. researchers to address the emerging problems of neurological diseases in HIV-infected individuals in understudied regions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Center Core Grants (P30)
Project #
3P30MH062261-12S1
Application #
8511864
Study Section
Special Emphasis Panel (ZMH1-ERB-M)
Project Start
Project End
Budget Start
2012-07-03
Budget End
2013-02-28
Support Year
12
Fiscal Year
2012
Total Cost
$11,250
Indirect Cost
$3,674
Name
University of Nebraska Medical Center
Department
Type
DUNS #
168559177
City
Omaha
State
NE
Country
United States
Zip Code
68198
Sathyanesan, Monica; Watt, Michael J; Haiar, Jacob M et al. (2018) Carbamoylated erythropoietin modulates cognitive outcomes of social defeat and differentially regulates gene expression in the dorsal and ventral hippocampus. Transl Psychiatry 8:113
Zhou, Tian; Su, Hang; Dash, Prasanta et al. (2018) Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. Biomaterials 151:53-65
Thangaraj, Annadurai; Periyasamy, Palsamy; Liao, Ke et al. (2018) HIV-1 TAT-mediated microglial activation: role of mitochondrial dysfunction and defective mitophagy. Autophagy 14:1596-1619
Kevadiya, Bhavesh D; Ottemann, Brendan M; Thomas, Midhun Ben et al. (2018) Neurotheranostics as personalized medicines. Adv Drug Deliv Rev :
Wiesman, Alex I; O'Neill, Jennifer; Mills, Mackenzie S et al. (2018) Aberrant occipital dynamics differentiate HIV-infected patients with and without cognitive impairment. Brain 141:1678-1690
Periyasamy, Palsamy; Thangaraj, Annadurai; Guo, Ming-Lei et al. (2018) Epigenetic Promoter DNA Methylation of miR-124 Promotes HIV-1 Tat-Mediated Microglial Activation via MECP2-STAT3 Axis. J Neurosci 38:5367-5383
Zhou, Tian; Lin, Zhiyi; Puligujja, Pavan et al. (2018) Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals. Nanomedicine (Lond) 13:871-885
Yang, Lu; Niu, Fang; Yao, Honghong et al. (2018) Exosomal miR-9 Released from HIV Tat Stimulated Astrocytes Mediates Microglial Migration. J Neuroimmune Pharmacol 13:330-344
Lin, Zhiyi; Gautam, Nagsen; Alnouti, Yazen et al. (2018) ProTide generated long-acting abacavir nanoformulations. Chem Commun (Camb) 54:8371-8374
McMillan, JoEllyn; Szlachetka, Adam; Zhou, Tian et al. (2018) Pharmacokinetic testing of a first generation cabotegravir prodrug in rhesus macaques. AIDS :

Showing the most recent 10 out of 374 publications